- PROFESSOR Psychiatry
Am Board of Psychiatry & Neurology (Sub: Child)
Psychiatry, American Board of Psychiatry and Neurology
- Attention Deficit Hyperactivity Disorder And Attention Deficit Disorder
- Obsessive-Compulsive Disorder
- Tourette Syndrome
MD, Tufts University School of Medicine
Fellowship, Child and Adolescent Psychiatry
Tufts University School of Medicine
Dr. Coffey is an internationally known specialist in Tics and Tourette’s Disorder and related problems. She is Professor in the Department of Psychiatry and Chief of the Tics and Tourette’s Clinical and Research Program at the Icahn School of Medicine at Mount Sinai. She also serves as a Research Psychiatrist at the Nathan S. Kline Institute of Psychiatric Research in Orangeburg, New York. Prior to her move to the School of Medicine, Dr. Coffey was Associate Professor in the Department of Child and Adolescent Psychiatry at the NYU School of Medicine, and Director of the Tics and Tourette’s Clinical and Research Program at the NYU Child Study Center.
Dr. Coffey received her B.A. in Biology and Psychology from the University of Rochester, her M.D. from Tufts University School of Medicine and her M.S. in Epidemiology from the Harvard School of Public Health. She completed a residency in general psychiatry at Boston University School of Medicine and a fellowship in child and adolescent psychiatry at the Tufts University School of Medicine.
Dr. Coffey held past positions as Director of Pediatric Psychopharmacology at McLean Hospital and Director of the Tourette's Clinics at McLean and Massachusetts General Hospitals in Boston between 1992 and 2001, and remained on the faculty of the Harvard Medical School as a Clinical Associate at Massachusetts General Hospital until January 2007. Dr. Coffey has repeatedly been recognized by America’s Best Doctors, Boston’s Best Doctors, and New York’s Best Doctors.
Dr. Coffey has served in major national leadership positions in the American Academy of Child and Adolescent Psychiatry (AACAP) and was recently appointed as North American representative on the Child and Adolescent Psychiatry Section of the World Psychiatric Association. As a former member of the Medical Advisory Board of the Tourette Syndrome Association (TSA), and recipient of a TSA Massachusetts Chapter award, Dr. Coffey has served on the Speakers’ Bureau of the joint TSA-CDC Partnership for educational programs throughout the US, and has received ongoing research funding from the organization.
Dr. Coffey served on the Committee on Written Examination in Child and Adolescent Psychiatry and the Steering Committee on Certification in Child and Adolescent Psychiatry for the American Board of Psychiatry and Neurology. In addition, Dr. Coffey has served as an Associate Editor of the Journal of Child and AdolescentPsychopharmacology.
ResearchDr. Coffey’s research has focused on the clinical course, comorbidity, phenomenology, and treatment of Tourette’s Disorder and related problems.
A unique focus of Dr. Coffey’s work has been comorbid anxiety and mood disorders in TD. She initially reported that separation anxiety disorder, independent of OCD, predicted greater tic severity, and that major mood disorders were a more robust predictor of functional impairment than tic severity in youth with TD. More recently, Dr. Coffey and her colleagues are investigating the neurobiology of TD with both genomics and neuroimaging techniques.
Lebowitz ER, Motlagh MG, Katsovich L, King RA, Lombroso PJ, Grantz H, Lin H, Bentley MJ, Gilbert DL, Singer HS, Coffey BJ, Kurlan RM, Leckman JF. Tourette syndrome in youth with and without obsessive compulsive disorder and attention deficit hyperactivity disorder. European child & adolescent psychiatry 2012 Aug; 21(8).
Gabbay V, Babb JS, Klein RG, Panzer AM, Katz Y, Alonso CM, Petkova E, Wang J, Coffey BJ. A double-blind, placebo-controlled trial of ω-3 fatty acids in Tourette's disorder. Pediatrics 2012 Jun; 129(6).
Kurlan R, Crespi G, Coffey B, Mueller-Vahl K, Koval S, Wunderlich G. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Movement disorders : official journal of the Movement Disorder Society 2012 May; 27(6).
Coffey B, Rapoport J. Guest Editors, Special issue: Tourette’s disorder and obsessive compulsive disorder. Journal of Child and Adolescent Psychopharmacology 2010; 20(4): 235-236.
Lyon GJ, Samar SM, Conelea C, Trujillo MR, Lipinski CM, Bauer CC, Brandt BC, Kemp JJ, Lawrence ZE, Howard J, Castellanos FX, Woods D, Coffey BJ. Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder. Journal of child and adolescent psychopharmacology 2010 Aug; 20(4).
Lyon GJ, Samar S, Jummani R, Hirsch S, Spirgel A, Goldman R, Coffey BJ. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. Journal of child and adolescent psychopharmacology 2009 Dec; 19(6).
Gabbay V, Coffey BJ, Guttman LE, Gottlieb L, Katz Y, Babb JS, Hamamoto MM, Gonzalez CJ. A cytokine study in children and adolescents with Tourette's disorder. Progress in neuro-psychopharmacology & biological psychiatry 2009 Aug; 33(6).
Budman C, Coffey BJ, Shechter R, Schrock M, Wieland N, Spirgel A, Simon E. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. Journal of child and adolescent psychopharmacology 2008 Oct; 18(5).
Gabbay V, Coffey BJ, Babb JS, Meyer L, Wachtel C, Anam S, Rabinovitz B. Pediatric autoimmune neuropsychiatric disorders associated with streptococcus: comparison of diagnosis and treatment in the community and at a specialty clinic. Pediatrics 2008 Aug; 122(2).
Kurlan R, Johnson D, Kaplan EL. Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study. Pediatrics 2008 Jun; 121(6).
Coffey BJ, Biederman J, Geller D, Frazier J, Spencer T, Doyle R, Gianini L, Small A, Frisone DF, Magovcevic M, Stein N, Faraone SV. Reexamining Tic persistence and Tic-associated impairment in Tourette's Disorder: findings from a naturalistic follow-up study. The Journal of nervous and mental disease 2004 Nov; 192(11).
Wilhelm S, Deckersbach T, Coffey BJ, Bohne A, Peterson AL, Baer L. Habit reversal versus supportive psychotherapy for Tourette's disorder: a randomized controlled trial. The American journal of psychiatry 2003 Jun; 160(6).
Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002 Feb; 58(4).
Spencer TJ, Biederman J, Faraone S, Mick E, Coffey B, Geller D, Kagan J, Bearman SK, Wilens T. Impact of tic disorders on ADHD outcome across the life cycle: findings from a large group of adults with and without ADHD. The American journal of psychiatry 2001 Apr; 158(4).
Coffey BJ, Biederman J, Geller DA, Spencer TJ, Kim GS, Bellordre CA, Frazier JA, Cradock K, Magovcevic M. Distinguishing illness severity from tic severity in children and adolescents with Tourette's disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2000 May; 39(5).
Coffey BJ, Biederman J, Spencer T, Geller DA, Faraone SV, Bellordre CA. Informativeness of structured diagnostic interviews in the identification of Tourette's disorder in referred youth. The Journal of nervous and mental disease 2000 Sep; 188(9).
Coffey BJ, Biederman J, Smoller JW, Geller DA, Sarin P, Schwartz S, Kim GS. Anxiety disorders and tic severity in juveniles with Tourette's disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2000 May; 39(5).
Coffey BJ, Miguel EC, Biederman J, Baer L, Rauch SL, O'Sullivan RL, Savage CR, Phillips K, Borgman A, Green-Leibovitz MI, Moore E, Park KS, Jenike MA. Tourette's disorder with and without obsessive-compulsive disorder in adults: are they different?. The Journal of nervous and mental disease 1998 Apr; 186(4).
- Guanfacine in Children with Tourette's Disorder
- Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder
- A 6-Month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents with Tourette's Disorder (TD)
- A Pilot Study of SD-809 (deutetrabenazine) in Moderate to Severe Tourette Syndrome
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Coffey during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Genco Sciences Europe Limited
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
One Gustave L. Levy Place
New York, NY 10029
1240 Park Avenue Floor 1st Floor Room 3
New York, NY 10029
1240 Park Avenue
1st FLoor Room 3
New York, NY 10029
- Monday 9:00am - 5:00pm
- Tuesday 9:00am - 5:00pm
- Wednesday 9:00am - 5:00pm
- Thursday 9:00am - 5:00pm
- Friday 9:00am - 5:00pm
- Personal Check